Summary

Gene Therapy Market Size, Share, and Analysis, By Type (Gene Silencing, Gene Augmentation, Cell Replacement, Other Therapies), By Vector (Viral Vectors, Non-Viral Vectors), By Therapeutic Area (Neurology, Oncology, Hepatology, Other Therapeutic Areas), By Delivery Method (In Vivo, Ex Vivo), By Route of Administration (Intravenous, Other Routes of Administration) and By Region (North America, Europe, Asia-Pacific, And Rest of the World) And Regional Forecast 2024-2034

PRODUCT OVERVIEW
Gene Therapy Market is anticipated to grow at a CAGR of 20.4% in the forecast period (2024-2034), with the market size valued at USD 8.6 billion in 2023 and projected to reach USD 66.8 billion by 2034.
Gene therapy is a revolutionary medical technique aimed at treating or curing genetic disorders by modifying the genetic material within a patient's cells. This approach involves the addition, removal, or alteration of genetic material to correct defective genes responsible for disease. There are two main types of gene therapy: in vivo (delivered directly into the patient's body) and ex vivo (where cells are genetically modified outside the body and then reintroduced). Gene therapy holds promise for treating various conditions, including genetic disorders, certain cancers, and viral infections. Despite its potential, challenges such as high costs, technical difficulties, and ethical concerns continue to influence the development and application of gene therapy.

MARKET HIGHLIGHTS
The Gene Therapy Market is projected to grow at a compound annual growth rate (CAGR) of 20.4% from 2024 to 2034, reaching an estimated value of USD 66.8 billion. This growth is driven by advances in genetic engineering technologies like CRISPR and viral vector technologies, which enhance the precision and efficacy of gene therapies. The increasing prevalence of genetic disorders and the demand for targeted therapies are boosting interest in the market. Significant investments in research and development from both public and private sectors are driving innovation and expanding the pipeline of gene therapy treatments. Regulatory approvals and supportive policies further propel market growth. The future of gene therapy looks promising with its increasing application in treating cancer and rare diseases, improvements in delivery methods, and potential reduction in treatment costs, all contributing to the market's expansion and progress in personalized medicine.

Gene Therapy Market Segments:

• By Type
o Gene Silencing
o Gene Augmentation
o Cell Replacement
o Other Therapies
• By Vector
o Viral Vectors
o Non-Viral Vectors
• By Therapeutic Area
o Neurology
o Oncology
o Hepatology
o Other Therapeutic Areas
• By Delivery Method
o In Vivo
o Ex Vivo
• By Route of Administration
o Intravenous
o Other Routes of Administration


MARKET DYNAMICS
Growth Drivers
Advancements in Gene Editing Technologies to Provide Market Growth and Expansion Opportunities
Increased Regulatory Approvals for Gene Therapies is Expanding Market Access
Restraint
Manufacturing Complexities Can Hinder Growth and Development Opportunities

Key Players
• Novartis
• Spark Therapeutics
• Regenxbio
• Gilead Sciences
• CRISPR Therapeutics
• Vertex Pharmaceuticals
• Pfizer
• Bluebird Bio
• Bayer AG
• AstraZeneca
• Sangamo Therapeutics
• Merck KGaA
• Astellas Pharma
• Takeda Pharmaceutical
• BioMarin Pharmaceutical
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Global Laboratory Temperature Control Units Market is further segmented by region into:
• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 3-month post-sales analyst support.

ページTOPに戻る

Table of Contents

1.Executive Summary
1.1. Regional Market Share
1.2.Business Trends
1.3. Gene Therapy Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1.Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4.Primary Research
2.5.Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1.Market Definition
3.2.Gene Therapy Market: COVID-19 Impact
3.3. Key Segmentations
3.4.Key Developments
3.5.Allied Industry Data
4.Gene Therapy Market – Industry Insights
4.1. Industry Segmentation
4.2.COVID-19 overview of world economy
4.3.Industry Ecosystem Channel Analysis
4.4.Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1.Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4.Market Restraints
7.5. Market Trends
8.Risk Analysis
9. Market Analysis
9.1.Porter's Five Forces
9.2. PEST Analysis
9.2.1.Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10.Gene Therapy Market
10.1.Overview
10.2. Historical Analysis (2018-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Gene Therapy Market Size & Forecast 2024A-2034F
11.1. Overview
11.2.Key Findings
11.3.Market Segmentation
11.3.1.By Type
11.3.1.1. Gene Silencing
11.3.1.1.1.By Value (USD Million) 2024A-2034F
11.3.1.1.2. Market Share (%) 2024A-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.2.Gene Augmentation
11.3.1.2.1. By Value (USD Million) 2024A-2034F
11.3.1.2.2.Market Share (%) 2024A-2034F
11.3.1.2.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.3.Cell Replacement
11.3.1.3.1. By Value (USD Million) 2024A-2034F
11.3.1.3.2.Market Share (%) 2024A-2034F
11.3.1.3.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.4.Other Therapies
11.3.1.4.1. By Value (USD Million) 2024A-2034F
11.3.1.4.2.Market Share (%) 2024A-2034F
11.3.1.4.3.Y-o-Y Growth (%) 2024A-2034F
11.3.2. By Vector
11.3.2.1.Viral Vectors
11.3.2.1.1. By Value (USD Million) 2024A-2034F
11.3.2.1.2.Market Share (%) 2024A-2034F
11.3.2.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.2.2. Non-Viral Vectors
11.3.2.2.1.By Value (USD Million) 2024A-2034F
11.3.2.2.2. Market Share (%) 2024A-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.By Therapeutic Area
11.3.3.1.Neurology
11.3.3.1.1. By Value (USD Million) 2024A-2034F
11.3.3.1.2.Market Share (%) 2024A-2034F
11.3.3.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.3.2. Oncology
11.3.3.2.1.By Value (USD Million) 2024A-2034F
11.3.3.2.2. Market Share (%) 2024A-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.3. Hepatology
11.3.3.3.1.By Value (USD Million) 2024A-2034F
11.3.3.3.2. Market Share (%) 2024A-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.4. Other Therapeutic Areas
11.3.3.4.1.By Value (USD Million) 2024A-2034F
11.3.3.4.2. Market Share (%) 2024A-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.By Delivery Method
11.3.4.1.In-Vivo
11.3.4.1.1. By Value (USD Million) 2024A-2034F
11.3.4.1.2.Market Share (%) 2024A-2034F
11.3.4.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.4.2. Ex-Vivo
11.3.4.2.1.By Value (USD Million) 2024A-2034F
11.3.4.2.2. Market Share (%) 2024A-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.By Route of Administration
11.3.5.1.Intravenous
11.3.5.1.1. By Value (USD Million) 2024A-2034F
11.3.5.1.2.Market Share (%) 2024A-2034F
11.3.5.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.5.2. Other Routes of Administration
11.3.5.2.1.By Value (USD Million) 2024A-2034F
11.3.5.2.2. Market Share (%) 2024A-2034F
11.3.5.2.3. Y-o-Y Growth (%) 2024A-2034F
12.North America Gene Therapy Market Size & Forecast 2024A-2034F
12.1.Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1.By Type
12.3.2. By Vector
12.3.3. By Therapeutic Area
12.3.4. By Delivery Method
12.3.5. By Route of Administration
12.4. Country
12.4.1. United States
12.4.2. Canada
13.Europe Gene Therapy Market Size & Forecast 2024A-2034F
13.1.Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1.By Type
13.3.2. By Vector
13.3.3. By Therapeutic Area
13.3.4. By Delivery Method
13.3.5. By Route of Administration
13.4.Country
13.4.1.Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14.Asia-Pacific Gene Therapy Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3.Market Segmentation
14.3.1.By Type
14.3.2. By Vector
14.3.3. By Therapeutic Area
14.3.4. By Delivery Method
14.3.5. By Route of Administration
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4.Japan
14.4.5.Rest of APAC
15.Middle East and Africa Gene Therapy Market Size & Forecast 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1.By Type
15.3.2. By Vector
15.3.3. By Therapeutic Area
15.3.4. By Delivery Method
15.3.5. By Route of Administration
15.4.Country
15.4.1.Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4.South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Gene Therapy Market Size & Forecast 2024A-2034F
16.1.Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1.By Type
16.3.2. By Vector
16.3.3. By Therapeutic Area
16.3.4. By Delivery Method
16.3.5. By Route of Administration
16.4.Country
16.4.1.Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1.Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Novartis
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2.Key Clients
18.1.4.3.Market Share
18.1.4.4.Recent News & Development (Last 3 Yrs.)
18.2.Spark Therapeutics
18.3. Regenxbio
18.4. Gilead Sciences
18.5. CRISPR Therapeutics
18.6. Vertex Pharmaceuticals
18.7. Pfizer
18.8. Bluebird Bio
18.9. Bayer AG
18.10. AstraZeneca
18.11.Sangamo Therapeutics
18.12. Merck KGaA
18.13. Astellas Pharma
18.14. Takeda Pharmaceutical
18.15. BioMarin Pharmaceutical
18.16. Other Prominent Players
19. Appendix
20.Consultant Recommendation